Please login to the form below

Not currently logged in

Orrin Pollard joins behavioural change agency Hamell

Theformer DDB Remedy chairman takes up an executive creative director role

Hamell Orrin PollardHamell has appointed Orrin Pollard as a partner and executive creative director in a role that will see him help launch new communications division Hamell Ignyte.

Pollard has been chairman at DDB remedy for 11 years, prior to which he was director and creative director at UK healthcare advertising agency Leavold Pollard Bardsley for eight years.

He said: “Many agencies talk about changing behaviour, but few actually have the evidence to back it up. “This is where Hamell Ignyte differs, because through our behavioural research division Hamell Spark, [and its] unique, validated methodology, we are able to get under the skin and into the minds of our target audiences to really discover their motivators and behavioural drivers.”

London-based agency Hamell was formed in 2008 and its new comms division will be driven by Pollard and Hamell's managing director Fiona Hammond and clinical director Alison Carr.

Commenting on Pollard's appointment, Hammond said: “We are absolutely thrilled that Orrin is joining us here at Hamell. He brings with him a wealth of experience, and his proven expertise will enable us to realise our vision of creating innovative communication solutions that facilitate real and lasting behavioural change.

“This is a step forward for Hamell and comes hot on the heels of some major new business wins in behavioural research. We are excited to be growing our full service agency and translating more of our in-depth behavioural insights into communications supported by memorable, engaging creative.”

10th November 2015

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?